A Cancer vaccine cured 97% of tumors in mice and human trials will begin soon! That’s unbelievably great news. The vaccine-like injection stimulates the body’s T cells, which are important for fighting tumors.
An injectable “vaccine” delivered directly to tumors in mice has been found to eliminate all traces of those tumors, cancer researchers have found – and it works on many different kinds of cancers, including untreated metastases in the same animal.
Scientists at Stanford University School of Medicine have developed the potential treatment using two agents that boost the body’s immune system, and a human clinical trial in lymphoma patients is currently underway.
“When we use these two agents together, we see the elimination of tumours all over the body,” said senior researcher, oncologist Ronald Levy.
The researchers believe the local application of very small amounts of the agents could serve as a rapid and relatively inexpensive cancer therapy which is unlikely to cause the adverse side effects often seen with body-wide immunotherapy.
When we use these two agents together, we see the elimination of tumors all over the body, says Ronald Levy, MD, professor of oncology. One agent is already approved for use in humans. The second one has been tested for human use in several unrelated clinical trials. The Stanford vaccine could be much cheaper and easier for patients.
To test it, laboratory mice were transplanted with mouse lymphoma in two places, or genetically engineered to develop breast cancer. Of the 90 mice with lymphoma, 87 were completely cured – the treatment was injected into one tumor, and both were destroyed. The remaining 3 had a recurrence of the lymphoma, which cleared up after a second treatment.
The treatment was also effective on the mice genetically engineered to develop breast cancer. Treating the first tumor often, but not always, prevented the recurrence of tumors, and increased the animals’ lifespan, the researchers said.
The team then tested mice with both lymphoma and colon cancer, injecting only the lymphoma. The lymphoma was destroyed, but the colon cancer was not. This demonstrates that T cells in tumors are specific to that kind of tumor – so the treatment isn’t without limitations.
The clinical trial currently underway is expected to recruit 15 patients with low-grade lymphoma to see if the treatment works on humans.